Rachel McMinn, Neurogene CEO
After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic
When former analyst Rachel McMinn started Neurogene from her apartment around three years ago, she would joke that they’d get office space as soon as her living room table was no longer big enough to hold company meetings.
“We lasted about a year before my living room couldn’t take it anymore,” she said.
With several gene therapies for Batten disease and other lysosomal storage disorders in the preclinical and discovery stage, Neurogene is now bound for the clinic. And on Wednesday, they announced a $115 million Series B to get them there.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
